12.46

3.83% 0.46

After Hours: 12.46

Celcuity Inc (CELC)

Overview News Price History Option Chain Financials Discussions Forecast

Celcuity Inc stock is traded at $12.46, with a volume of 1.09M. It is up +3.83% in the last 24 hours and down -2.50% over the past month. Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Previous Close:

$12.00

Open:

$11.85

24h Volume:

1.09M

Relative Volume:

4.11

Market Cap:

$462.63M

Revenue:

Net Income/Loss:

$-63.78M

P/E Ratio:

-4.7019

EPS:

-2.65

Net Cash Flow:

$-53.91M

1W Performance:

-0.48%

1M Performance:

-2.50%

6M Performance:

-19.97%

1Y Performance:

-13.59%

1-Day Range:

$11.62

$12.59

1-Week Range:

$11.62

$13.02

52-Week Range:

$11.51

$22.19

Celcuity Inc Stock (CELC) Company Profile

Name

Celcuity Inc

Sector

Healthcare (1176)

Industry

Biotechnology (673)

Phone

763-392-0767

Address

16305 36TH AVENUE N, MINNEAPOLIS, MN

Employee

Twitter

Next Earnings Date

2024-11-11

Latest SEC Filings

CELC's Discussions on Twitter

Compare CELC with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CELC Celcuity Inc	12.46	462.63M	0	-63.78M	-53.91M	-2.68
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Celcuity Inc Stock (CELC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-22-24	Initiated	Leerink Partners	Outperform
Feb-22-24	Initiated	Stifel	Buy
Dec-08-23	Initiated	H.C. Wainwright	Buy
Oct-08-21	Initiated	Canaccord Genuity	Buy
Sep-07-21	Initiated	Jefferies	Buy
Jul-29-21	Initiated	Cowen	Outperform
Jul-27-21	Initiated	Needham	Buy
Jan-28-21	Reiterated	H.C. Wainwright	Buy
Dec-24-20	Reiterated	H.C. Wainwright	Buy
May-11-20	Resumed	Craig Hallum	Buy
Nov-20-18	Initiated	H.C. Wainwright	Buy

View All

Celcuity Inc Stock (CELC) Latest News

Dec 20, 2024

Celcuity Inc. (NASDAQ:CELC) Given Average Rating of "Buy" by Analysts - MarketBeat

Dec 20, 2024

Wellington Management Group LLP Makes New Investment in Celcuity Inc. (NASDAQ:CELC) - MarketBeat

Dec 20, 2024

Dec 17, 2024

Celcuity (CELC) Charges Forward with Promising Potential Cancer Treatments - TipRanks

Dec 17, 2024

Dec 16, 2024

Celcuity Inc. (NASDAQ:CELC) Short Interest Update - MarketBeat

Dec 16, 2024

Dec 15, 2024

Charles Schwab Investment Management Inc. Acquires 153,712 Shares of Celcuity Inc. (NASDAQ:CELC) - MarketBeat

Dec 15, 2024

Dec 13, 2024

BNP Paribas Financial Markets Raises Holdings in Celcuity Inc. (NASDAQ:CELC) - MarketBeat

Dec 13, 2024

BNP Paribas Financial Markets Has $673,000 Stake in Celcuity Inc. (NASDAQ:CELC) - Defense World

Dec 13, 2024

Dec 11, 2024

Celcuity reports survival data for breast cancer drug - Investing.com

Dec 11, 2024

Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium - The Manila Times

Dec 11, 2024

Celcuity Presents Overall Survival Data from Phase 1b Study - GlobeNewswire

Dec 11, 2024

Verition Fund Management LLC Reduces Holdings in Celcuity Inc. (NASDAQ:CELC) - MarketBeat

Dec 11, 2024

Nov 30, 2024

Braidwell LP Buys 367,663 Shares of Celcuity Inc. (NASDAQ:CELC) - MarketBeat

Nov 30, 2024

Nov 25, 2024

Celcuity Inc. (NASDAQ:CELC) Given Consensus Rating of "Buy" by Brokerages - MarketBeat

Nov 25, 2024

Nov 21, 2024

(CELC) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Nov 21, 2024

Nov 18, 2024

Celcuity’s (CELC) “Buy” Rating Reiterated at Needham & Company LLC - Defense World

Nov 18, 2024

Earnings call: Celcuity reports Q3 2024 financials and clinical trial updates - Investing.com

Nov 15, 2024

Celcuity's (CELC) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat

Nov 15, 2024

Celcuity Inc. (NASDAQ:CELC) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 15, 2024

RA Capital Management, L.P. Acquires New Stake in Celcuity Inc - GuruFocus.com

Nov 15, 2024